Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
NCT07788118Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 7×19-THEMIS CAR-T cells in diffuse large B-cell lymphoma (DLBCL), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Recommended Phase II Dose at 3 months, Objective Response Rate at 3 months and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
7×19-THEMIS CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07788118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788118.